Benzinga | Aug 6, 2020 04:00PM EDT

Earnings Outlook for Meridian Bioscience

On Friday, August 07, Meridian Bioscience (NASDAQ: VIVO) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Earnings and Revenue

Based on Meridian Bioscience management projections, analysts predict EPS of $0.25 on revenue of $66.04 million. In the same quarter last year, Meridian Bioscience announced EPS of $0.16 on revenue of $48.44 million. If the company were to post earnings in-line with the consensus estimate when it reports Friday, EPS would be up 56.25%. Here's how the company's reported EPS has compared to analyst estimates in the past:

Quarter Q2 2020 Q1 2020 Q4 2019 Q3 2019EPS Estimate 0.08 0.07 0.09 0.09EPS Actual 0.23 0.10 0.13 0.16Revenue Estimate 49.26 M 48.90 M 50.59 M 49.81 MRevenue Actual 57.30 M 47.42 M 50.85 M 48.44 M

Stock Performance

Over the last 52-week period, shares are up 117.93%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.

Don't be surprised to see the stock move on comments made during its conference call. Meridian Bioscience is scheduled to hold the call at 10:00:00 ET and can be accessed here: https://investor.meridianbioscience.com/events/event-details/q3-2020-financial-results-conference-call